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Abstract
Background: Ovarian cancer kills approximately 15,000 women in the United States every year, and more than 140,000
women worldwide. Most deaths from ovarian cancer are caused by tumors of the serous histological type, which are rarely
diagnosed before the cancer has spread. Rational design of a potentially life-saving early detection and intervention
strategy requires understanding the lesions we must detect in order to prevent lethal progression. Little is known about the
natural history of lethal serous ovarian cancers before they become clinically apparent. We can learn about this occult
period by studying the unsuspected serous cancers that are discovered in a small fraction of apparently healthy women
who undergo prophylactic bilateral salpingo-oophorectomy (PBSO).
Methods and Findings: We developed models for the growth, progression, and detection of occult serous cancers on the
basis of a comprehensive analysis of published data on serous cancers discovered by PBSO in BRCA1 mutation carriers. Our
analysis yielded several critical insights into the early natural history of serous ovarian cancer. First, these cancers spend on
average more than 4 y as in situ, stage I, or stage II cancers and approximately 1 y as stage III or IV cancers before they
become clinically apparent. Second, for most of the occult period, serous cancers are less than 1 cm in diameter, and not
visible on gross examination of the ovaries and Fallopian tubes. Third, the median diameter of a serous ovarian cancer when
it progresses to an advanced stage (stage III or IV) is about 3 cm. Fourth, to achieve 50% sensitivity in detecting tumors
before they advance to stage III, an annual screen would need to detect tumors of 1.3 cm in diameter; 80% detection
sensitivity would require detecting tumors less than 0.4 cm in diameter. Fifth, to achieve a 50% reduction in serous ovarian
cancer mortality with an annual screen, a test would need to detect tumors of 0.5 cm in diameter.
Conclusions: Our analysis has formalized essential conditions for successful early detection of serous ovarian cancer.
Although the window of opportunity for early detection of these cancers lasts for several years, developing a test sufficiently
sensitive and specific to take advantage of that opportunity will be a challenge. We estimated that the tumors we would
need to detect to achieve even 50% sensitivity are more than 200 times smaller than the clinically apparent serous cancers
typically used to evaluate performance of candidate biomarkers; none of the biomarker assays reported to date comes close
to the required level of performance. Overcoming the signal-to-noise problem inherent in detection of tiny tumors will likely
require discovery of truly cancer-specific biomarkers or development of novel approaches beyond traditional blood protein
biomarkers. While this study was limited to ovarian cancers of serous histological type and to those arising in BRCA1
mutation carriers specifically, we believe that the results are relevant to other hereditary serous cancers and to sporadic
ovarian cancers. A similar approach could be applied to other cancers to aid in defining their early natural history and to
guide rational design of an early detection strategy.
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In 2007, ovarian cancer is estimated to have killed more than
15,000 women in the United States [1] and more than 140,000
worldwide [2]. The majority of these deaths were from ovarian
cancer of the serous histological type. The other histological
subtypes of ovarian cancer differ substantially in their molecular
features and natural history and can be considered distinct diseases
[3,4]. Ovarian carcinomas of the serous histological type are an
attractive target for early detection as they are rarely detected
before they reach an advanced stage, when they are highly lethal
[5]. The success of early intervention strategies for other cancers,
including prostate, colon, and cervical cancer, gives us hope that
early detection of ovarian cancer could be an effective way to save
lives [6].
In order to save lives by early detection we need to detect and
eliminate tumors that would otherwise ultimately be lethal. We
know surprisingly little about the target for early detection of
serous ovarian cancer. What do lethal serous ovarian cancers look
like during the ‘‘window of opportunity’’—the period before they
become incurable? It is sometimes implicitly assumed that the
ovarian cancers that present clinically at early stages represent the
precursors to cancers that present at advanced stages, but the
evidence argues strongly against this model. For example, few
ovarian cancers that present at stage I are of serous histology, yet
most ovarian cancers that present at stage III or IV are serous
[4,5]. Clearly it would be a mistake to assume that nonserous stage
I cancers transform into advanced-stage serous cancers. Similarly,
we cannot simply assume that advanced serous cancers, although
histologically similar, were once equivalent to the rare serous
cancers that are clinically diagnosed at stage I. By defining the
what, when, and where of preclinical ovarian cancer, we can begin
to rationally design an effective early detection strategy.
The ideal approach to defining the early natural history of a
cancer would be to carefully observe tumor development from
genesis through late stage without intervening. While this ideal
study is not feasible, we can still clarify many aspects of the early
natural history of ovarian cancer by taking advantage of data from
prophylactic bilateral salpingo-oophorectomies (PBSOs) (surgical
removal of both fallopian tubes and ovaries). Many apparently
healthy women with a family history of ovarian cancer choose to
undergo this procedure, which has been proven to reduce
mortality from ovarian cancer [7–10]. In a small fraction of these
women, an unsuspected cancer is discovered [7–26]. We can
estimate the duration of the window of opportunity for early
detection by comparing the prevalence of nonadvanced occult
serous cancers in these PBSO specimens with the incidence of
serous ovarian cancer in a comparable population [27]. Further-
more, the size and stage distribution of these occult tumors
provides a basis for modeling the growth and progression of
tumors that an early detection test must identify.
Here, we present a summary and analysis of available reports
describing the frequency and characteristics of occult serous
cancers discovered in prospective series of PBSOs in women at
known genetic risk of serous ovarian cancer. We focused our
analyses on women with mutations in the BRCA1 gene, the most
common genetic risk factor, for the sake of homogeneity and the
ability to synthesize and compare data from multiple reports
[8,28,29]. Using these data, we developed a model for the
preclinical natural history of serous ovarian cancer and considered
its implications for early detection. Our findings help to define the
performance requirements for early detection biomarkers and
screening modalities.
Methods
Our modeling strategy is schematized in Figure 1. The data
sources and details of the methods are described below. Further
details on the modeling methods and the full R [30] code are
available in Texts S1, S2, S3, S4, S5.
Data Sources
Sizes and stages of occult tumors. Sizes and stages of
occult tumors (Figure 1, Data 1) were taken directly from the
PBSO studies when possible. Twelve tumors that were described
as microscopic (detected by microscopic examination but not by
gross examination), but for which specific dimensions were not
provided, were assumed to have the same size distribution as the
21 tumors in these studies that were also described as
microscopic (by the same definition) for which the specific
dimensions were reported. In four cases where multiple tumors
were found in a single patient, we assumed that the tumors were
spheres of the specified diameter(s) and used as our ‘‘diameter’’
estimate the diameter of a sphere with a volume equivalent to
the total estimated volume of the tumors. Complete size and
stage data as reported in the referenced studies are reported in
Table S1.
Prevalence estimates. Our prevalence estimates were based
on a comprehensive review of all available data from published
series of PBSOs (Figure 1, Data 2) [8–18,20–22,24,31,32]. Our
criteria for study inclusion were: (1) the prophylactic procedure
included removal and microscopic examination of both ovaries
and both Fallopian tubes; (2) tumor histology was reported; (3)
patient genotypes were reported; (4) genotyping was done prior to
cancer diagnosis. The requirement for careful examination of both
Fallopian tube and ovaries was based on evidence that serous
‘‘ovarian’’ cancers can arise initially in either the Fallopian tubes
or the ovaries [20,31,33,34]. Occult cancers were defined as
cancerous lesions that were neither detected nor suspected prior to
surgery, including carcinoma in situ (CIS) and stage I–IV cancers,
but not atypical hyperplasia. Further details of the studies we
reviewed for prevalence estimates are available in Table S1.
Incidence estimates. Our estimate of the incidence of serous
ovarian cancer in BRCA1 women was based on a comprehensive
review of all available data from systematic studies of the incidence
of ovarian cancer in high-risk populations (Figure 1, Data 3) [8–
18,20–22,24,31,32]. Our inclusion criteria were: (1) the study
design must be prospective; (2) patients must have been genotyped
prior to cancer diagnosis. The mean age of the population on
which the incidence calculation was based had demographics very
similar to the set of patients who underwent PBSO (mean age
45.7 y for prevalence; 46.9 y for incidence). Further details of the
studies we reviewed are available in Table S2.
Sizes of tumors at clinical diagnosis. We modeled the
distribution of sizes at which tumors would be diagnosed in high-
risk populations based on the size distribution of serous tumors
detected in a large trial of screening for early detection (Figures 1,
Data 4 and S1) [35]. Our rationale was that the high-risk women
on whom our prevalence and incidence estimates were based were
likely to have been more closely monitored than women in the
general population. This study included sizes for 17 screen-
detected tumors but failed to report sizes for nine tumors that were
detected clinically between screens. These nine interval cancers
were assumed to have diameters log-normally distributed with a
mean of 8 cm; note that our sensitivity analyses indicated that
variation in this value over a range from 4–12 cm had a negligible
effect on results. For our estimates of early-detection screen
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women serous ovarian cancers present clinically at a diameter log-
normally distributed with a mean of 8 cm (P. Shaw and B. Rosen,
unpublished data; Figure S1).
Confidence Intervals for Estimates of Serous Cancer
Prevalence, Incidence, and Duration of Occult Intervals
Prevalence. We estimated the probability distribution of the
underlying prevalence of serous cancer in women with BRCA1
mutations, given the observed 32 cancers in 406 patients, using the
binomial distribution (Figure S2A). The 2.5th percentile and
97.5th percentile of this distribution gave the bounds of the 95%
confidence interval (CI) for the true prevalence.
Incidence. We estimated the probability distribution of the
underlying incidence of serous cancer in women with BRCA1
mutations, given the observed 36 serous cancers in 2,345 woman-
years, using the binomial distribution (Figure S2B). The 2.5th
percentile and 97.5th percentile of this distribution gave the
bounds of the 95% CI for the true incidence.
Duration of the occult period. The mean duration of the
occult period was estimated by prevalence/incidence (see Table
S1 for raw data). We used the ratio of 10,000 pairs of
(prevalence, incidence) values from the distributions described
above to estimate the probability distribution of the mean
duration of the occult period (Figure S2C). We used the same
approach to calculate the probability distributions for the
fraction of the occult period spent at CIS, stage I or stage II
(i.e., the ‘‘window of opportunity’’ for early detection) (Figure
S2D). The R [30] code used to make these CI calculations is
available in Text S1.
Modeling Stage Progression as a Function of Tumor Size
We modeled stage progression as a function of tumor size using
a Kaplan-Meier analysis analogous to a conventional Kaplan-
Meier analysis of progression as a function of time after diagnosis,
but replacing ‘‘time after diagnosis’’ with ‘‘tumor size,’’ censoring
observations at the size of the tumor at diagnosis (i.e., when
discovered by PBSO) (Figure 1, Method 1). We assumed that
serous tumors grow monotonically and that the likelihood of
having progressed from early to advanced stage increases with
time. For the primary analysis, we defined ‘‘early stage’’ to include
CIS, stage I and stage II cancers, and ‘‘advanced stage’’ to include
stage III and IV cancers. We estimated CIs for the Kaplan-Meier
survival curves by carrying out the Kaplan-Meier analysis on
1,000 simulated datasets generated by bootstrap resampling (with
normal kernel smoothing), of the 37 pairs of occult tumor (size,
stage) values obtained from the PBSO studies (Figure 1, Data 1,
see above). The tumors that were at an advanced stage when
discovered by PBSO had actually progressed to advanced stage at
some unknown time prior to their discovery. We therefore
assumed that detection of these advanced tumors by PBSO
occurred stochastically at times after progression to advanced stage
uniformly distributed between zero and the average time between
progression and clinical diagnosis. We could thus infer the sizes of
these advanced-stage tumors at progression on the basis of: (1)
tumor size at time of discovery by PBSO; (2) our estimate of the
duration of the advanced-occult period; (3) our estimate of the
growth rate of advanced tumors (see ‘‘Modeling tumor growth and
progression’’ below).
We carried out a second Kaplan-Meier analysis of progression
from (CIS and stage I) to (stages II, III, or IV) as a function of
tumor diameter (Figure S3). We estimated the sizes of stage II, III,
Figure 1. Schematic of our modeling strategy. The boxes outlined in blue represent the data that were used to build the model. The boxes
outlined in black represent critical steps in the modeling procedure. Data sources and modeling methods are described in Methods.
doi:10.1371/journal.pmed.1000114.g001
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sizes of these tumors when discovered by PBSO; (2) our estimates
of the average times spent at stage II or stage III+ prior to clinical
presentation; (3) our estimate of the growth rates of early or
advanced tumors, respectively. We again assumed that detection
of tumors by PBSO occurred stochastically at times after
progression to the stage at diagnosis, uniformly distributed
between zero and the average duration of the tumor stage at
detection by PBSO. The R code used for these analyses is
available in Text S2.
Modeling Tumor Growth
We used a Monte Carlo method to fit an exponential model for
tumor growth, with separate growth rate parameters for early
(CIS, stage I and stage II) and advanced (stage III and IV) tumors
(Figure 1, Method 2).
Early stage tumors were assumed to grow exponentially such
that: log(size)=a + (b * t1) where a=intercept (size at which the
tumor is detectable by histopathology); b=exponential growth rate
constant and t1 is the time since the tumor became detectable by
histopathology. To estimate a and b, we tested 625 pairs of (slope,
intercept) values (25 slope625 intercept). For each pair of values,
we modeled the growth of 1,000 hypothetical tumors according to
the specified parameters and compared the resulting distribution
of tumors to the observed data from PBSO studies. Specifically, we
chose the slope and intercept values that gave a distribution of
early-stage occult tumor sizes that best fit the sizes of early-stage
tumors discovered by PBSO, and a duration that fit our estimate
of the average duration of the early-stage occult period.
Advanced tumors were assumed to grow exponentially such
that: log(size)=c + (d * t2) where c=log(tumor diameter at
progression to advanced stage) obtained from the Kaplan-Meier
analysis; d=[log(mean size at diagnosis [from [35]])2log(mean
size at progression [from Kaplan Meir analysis])]/duration of
advanced occult period; t2=time since progression. The R code
used for this analysis is available in Text S2. Observed versus
model-predicted sizes of occult serous ovarian cancers are shown
in Figure S4.
Simulating Model Tumor Life Histories
We used a Monte Carlo method to generate models for the life
histories of 1,000 tumors, based on the following parameters: (1)
tumor growth rate; (2) probability of stage progression as a
function of size; (3) probability of clinical diagnosis as a function of
size (Figure 1, Method 3). Progression to stage III+ was assumed to
be stochastic and size-dependent; each of the 1,000 bootstrap
Kaplan-Meier analyses (above) was used to define risk of
progression as a function of size for one of the 1,000 model
tumors. Clinical diagnosis was assumed to be stochastic and size-
dependent. For high-risk women, the probability of clinical
diagnosis as a function of size was based on the size distribution
of serous tumors detected in a large trial of screening for early
detection [35]. For normal-risk women, we estimated the
probability of clinical diagnosis as a function of size by assuming
that tumors in this population are clinically diagnosed at diameters
log-normally distributed around a mean of 8 cm. The R code used
for this analysis is available in Text S2.
Estimating Sensitivity of Early Detection Testing
We estimated the sensitivity of hypothetical screening scenarios
by performing a hypothetical screening test in the 1,000 model
tumors described above (Figure 1, Method 4). We evaluated
sensitivity requirements as a function of the interval between tests
(3, 6, 12, or 24 mo) and the minimum diameter at which a
hypothetical test can detect a tumor. We assumed that the test
would always fail to detect an occult tumor below the size
threshold and would always succeed when the tumor size exceeded
the size threshold. Tests were considered positive when a
‘‘progressive tumor’’ (a tumor that would be diagnosed at an
advanced stage in the absence of screening) was above the size
threshold for detection but still less than stage III at the time of one
of the screening tests. Sensitivity in early detection was defined as
the number of true positive tests (i.e., tumors detected before
progression to stage III or IV) divided by the number of
‘‘progressive tumors’’ (tumors that would be diagnosed at an
advanced stage in the absence of screening). The R program used
for this analysis is available in Text S2.
Estimating Survival Benefits of Early Detection Testing
We estimated the 5-y survival benefits of hypothetical screening
scenarios by performing of a hypothetical screening test in the
1,000 model tumors described above, and combining the resulting
stage distribution with stage-specific survival data (Figure 1,
Method 5). We evaluated survival benefits as a function of the
interval between tests (3, 6, 12, or 24 mo) and the minimum
diameter at which a hypothetical test can detect a tumor. We
assumed that the test would always fail to detect an occult tumor
below the size threshold and would always succeed when the
tumor size exceeded the size threshold. We estimated the 5-y
survival benefit of a given screening scenario by comparing
mortality in the absence of screening to the mortality estimated
according to the distribution of stages of tumors detected with
screening given available stage-specific survival data for serous
cancers from SEER (1990–2004) [36]. The R program used for
this analysis is available in Text S2.
CIs for Model Outputs: Tumor Growth Rates, Sensitivity,
and Reduction in 5-y Mortality
We derived CIs for our estimates of early detection test
performance requirements based on 200 iterations of our entire
modeling procedure (Figure 1). In each of the 200 iterations, we
generated a set of input occult tumor sizes (n=37) by sampling
with replacement from the original set of 37 literature-derived
values (Figure 1, Data 1). We then repeated the Kaplan-Meier
analysis of stage progression as a function of tumor size (Figure 1,
Method 1), and Monte Carlo modeling of tumor growth (Figure 1,
Method 2) described above, for each set of 37 tumor sizes. Next,
for each of the resulting sets of functions, we generated a set of 25
model tumor life histories (Figure 1, Method 3) (i.e., 200 sets of 25
tumors). Each model tumor was assigned an occult period
duration and a size at clinical diagnosis by sampling with
replacement from the appropriate distribution (see Methods, data
sources above).
By applying a hypothetical annual screen to each of these 200 sets
of 25 model histories, we obtained 200 estimates of sensitivity
(Figure 1, Method 4) and 200 estimates of the improvement in 5-y
survival (Figure 1, Method 5), as a function of the threshold tumor
size for detection. Weobtained CIs directly from the results of the 200
iterations (see Figure S5). In Results, we report the 95% confidence
intervals for the tumor size detection threshold required to achieve a
specified sensitivity or mortality reduction (the upper limit of this
confidence interval is the tumor size threshold at which the specified
sensitivity was achieved in only 5 of the 200 sets of model tumor life
histories; the lower limit is the size threshold at which the specified
sensitivity was achieved in 195 of the 200 sets of model tumor life
histories). In addition, we estimated the probability densities for
tumor growth rates based on the 200 growth rate estimates derived as
described above (Figure S6).
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Parameters
We investigated the sensitivity of our model and our major
conclusions to systematic errors in the five key inputs: (1)
distribution of sizes of serous ovarian tumors at clinical
presentation in BRCA1 women; (2) distribution of sizes of serous
ovarian tumors at clinical presentation in the general population;
(3) duration of the occult period (e.g., due to sampling error or
systematic biases in our estimates of incidence and prevalence); (4)
Staging of the tumors discovered by PBSO; and (5) Fraction of
occult early-stage tumors that if left intact would ultimately be
diagnosed as ovarian cancer. In each case, the analyses were
performed by repeating the entire modeling procedure as outlined
in Figure 1, using altered values for the parameters in question.
For the first three of these parameters, we examined the effects of
varying the respective values between 50% and 200% of the best
available estimates from the data (our primary modeling inputs).
For staging, we examined how our conclusions would be altered if
we assumed that randomly selected subset comprising 0% to 100%
of the occult tumors discovered by PBSO were understaged by one
FIGO stage (i.e., stage I tumors were erroneously classified as CIS,
stage II tumors were erroneously classified as stage I, etc.). The
effects of changes in these variables on the tumor size detection
threshold needed to achieve a given level of early detection test
sensitivity or mortality benefit are shown in Figures S7 and S8,
respectively.
Results
The foundation of this study is a synthesis of data from
published studies describing occult serous ovarian cancers
discovered during prophylactic bilateral PBSO in BRCA1 women.
First, we summarized the characteristics of occult serous ovarian
tumors on the basis of these studies. Second, we built on these
results to model tumor growth, progression, and diagnosis. Lastly,
we examined the performance of hypothetical early detection tests
based on our tumor models. The data sources and modeling
approach are outlined in Figure 1.
Characteristics of Occult Serous Ovarian Cancers
We based our analysis of occult serous cancers on studies that
met the following criteria: (1) the prophylactic procedure included
removal and microscopic examination of both ovaries and both
Fallopian tubes; (2) tumor histology was reported; (3) patient
genotype was reported; (4) genotyping was done prior to cancer
diagnosis (for prevalence estimates only). Table 1 summarizes the
PBSO studies that met these criteria. By combining results across
studies, we obtained estimates for the prevalence, location, size,
and stage distribution of occult serous ovarian cancers in BRCA1
women (Table 2; Figure S2).
The Window of Opportunity for Early Detection
The duration of the ‘‘window of opportunity’’ for early
detection—the time during which detection of a tumor can be
acted upon to save lives—is a critical parameter in designing an
effective early detection strategy. We estimated the duration of
each stage in the preclinical progression of serous ovarian
tumors by dividing the prevalence of occult cancers at each
stage by the incidence of clinically diagnosed serous ovarian
cancer (irrespective of stage) in a population matched for age
(45.7 y for prevalence; 46.9 y for incidence) and genetic risk
(BRCA1 mutation carriers) [27]. In the eight studies that met our
inclusion criteria for calculating the prevalence of occult serous
cancers in women with BRCA1 mutations (Table 1), 32 occult
serous cancers were found in 406 PBSOs for an estimated
prevalence of 7.9% (95% CI 5.6–10.9%). In the two studies that
met our inclusion criteria for calculating incidence, there were
36 serous ovarian cancers in 2,345 woman-years, for an
estimated overall incidence of 1.5%/y (95% CI 1.1–2.1/y)
(Figure S2; Table S2) [8,32].
The prevalence/incidence calculation yielded an estimate of 5.1 y
(95% CI 3.2–8.1 y) for the median duration of the entire occult
period (clinically occult but potentially detectable by meticulous
histopathology). Similarly, we estimated the window of opportunity
for detection of early stage occult cancers (CIS, stage I, II) to be 4.3 y
(95% CI 2.6–6.9 y), and estimated that most serous cancers had
Table 1. Sources of occult tumor data (PBSO studies).
Study
BRCA1
Carriers (n)
Occult Serous
BRCA1 Cancers (n)
Early Occult Serous
BRCA1 Cancers (n)
BRCA1 Cohort
Age (Mean)
a
Included in
Prevalence
b
Finch et al., 2006 [15] 94 6 6 47 Y
Callahan et al., 2007 [12] 60 2 2 43 Y
Olivier et al., 2004 [21] 58 4 2 46 Y
Laki et al., 2007 [16] 56 3 3 48 Y
Powell et al., 2005 [22] 43 5 5 47 Y
Lamb et al., 2006 [17] 40 5 4 47 Y
Carcangiu et al., 2006 [13] 37 6 4 50 Y
Lu et al., 2000 [19] 18 1 1 46 Y
Colgan et al., 2001 [14] 27 1 1 NS N
Medeiros et al., 2006 [20] 6 1 1 55 N
Agoff et al., 2000 [11] ,29 3 2 NS N
Total — 37 31 — —
aMedian age was reported when mean age was not available. When mean age was not given for the BRCA1 subset, the mean age of the entire series is reported.
bSee Table S1 for rationale for exclusion/inclusion from prevalence calculations.
N, no; NS, age was not specified; Y, yes.
doi:10.1371/journal.pmed.1000114.t001
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(95% CI 0.4–1.9 y) prior to detection (see Figure S2).
Modeling Tumor Growth, Progression, and Diagnosis
Estimating growth rates of occult serous ovarian
cancers. We estimated the growth rates of early-stage (CIS,
stage I and stage II) and late-stage (stage III and IV) tumors
using a Monte Carlo method to fit an exponential growth model
to observed data (see Methods). The results suggest that early-
stage tumors double in volume, on average, approximately every
4 mo (10-fold per year), and that late-stage tumors double in
volume approximately every 2.5 mo (30-fold per year) (Figures
S4 and S6).
Modeling tumor progression as a function of size. We
used a Kaplan-Meier analysis to model tumor progression to late
stage (stage III or IV) as a function of tumor size (see Methods).
This approach was analogous to a conventional Kaplan-Meier
analysis of progression as a function of time after diagnosis, but
replacing ‘‘time after diagnosis’’ with ‘‘tumor size,’’ censoring
observations at the size of the tumor at diagnosis (i.e., when
discovered by PBSO). This analysis indicated that more than 50%
of serous tumors advanced to stage III/IV by the time they
reached 3 cm in diameter (Figures 2 and S3).
Estimating Early Detection Test Performance
Requirements
We used a Monte Carlo method to model the life trajectories of
1,000 serous cancers, on the basis of the growth parameters and
estimates of progression risk as a function of tumor size described
above, and estimates of the distribution of tumor sizes at clinical
presentation (Figure S1; Table S3) [35]. We then evaluated the
performance of hypothetical early detection strategies by applying
them to these 1,000 model tumors.
Estimating Early Detection Test Sensitivity Requirements
We assessed the performance requirements for an early
detection test by analyzing the sensitivity of hypothetical screening
tests as a function of the limit of detection of the test (tumor
diameter) and the interval between screens. We defined successful
early detection as detection of a tumor at stage II or earlier that
would otherwise be diagnosed at stage III or IV. This analysis was
based on our models for growth stage progression and tumor size
at clinical presentation as described above.
Our results indicated that in order to reach an overall sensitivity
of 50% in a normal-risk population, an annual screen would need
to reliably detect tumors of 1.3 cm or less in diameter. For a
sensitivity of 80%, the test would need to detect tumors of 0.4 cm
or less in diameter (Figure 3A). In a high-risk population subject to
careful conventional monitoring (i.e., similar to that in the
screening study described in [35]), an annual screen would need
to detect tumors of 1.1 cm and 0.4 cm to reach 50% or 80%
sensitivity, respectively (Figure 3B).
Estimating the Survival Benefit of Early Detection
We estimated the survival benefits of a hypothetical early
detection test using stage-specific survival data for serous ovarian
cancers [36], and a modeling strategy similar to that described
above for analyzing test sensitivity. Again, the key variables we
examined were size threshold for tumor detection and frequency
of a hypothetical early-detection screening test. The results of this
analysis suggest that a 50% reduction in 5-y mortality from serous
ovarian cancer in either a normal-risk (Figure 4A) or a high-risk
population (Figure 4B) could be achieved with an annual screen
capable of detecting a 0.4-cm tumor.
Figure 2. Tumor progression to late stage as a function of
tumor diameter. Kaplan-Meier analysis was used to model tumor
progression to late stage (III or IV) as a function of tumor diameter (see
Methods). Observations were censored at the size of the tumor when
discovered by PBSO. CIs are shown as indicated by the legend.
doi:10.1371/journal.pmed.1000114.g002
Table 2. Summary of key characteristics of occult tumors in
BRCA1 women.
Characteristics
Prevalence of occult tumors
Cancers/patients, n 32/406
Mean prevalence (95% CI) 7.9% (5.6%–11.0%)
Tumor size (early stage)
Tumors, n 31
Median diameter (95% CI) 3.0 mm (2.5–4.4 mm)
Tumor location, % (n)
FT, % (n) 59% (22)
Ovary, % (n) 24% (9)
FT and ovary, % (n) 11% (4)
Peritoneal, % (n)5 % ( 2 )
Total, n 37
Tumor stage
CIS, % (n) 24% (9)
Stage I, % (n) 43% (16)
Stage II, % (n) 16% (6)
Stage III, % (n) 14% (5)
Stage IV, % (n)3 % ( 1 )
Total, n 37
Abbreviation: FT, Fallopian tube.
doi:10.1371/journal.pmed.1000114.t002
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in the Data
We critically examined the sensitivity of our conclusions to
biases and uncertainties in the information on which they are
founded. We addressed both the potential effects of systematic
errors in empirically derived input parameters of our model, and
the confidence ranges of our major conclusions given the limited
number of tumors on which our analysis was based.
To determine CIs for our estimates of sensitivity and mortality
reduction, we repeated our modeling procedure (see Figure 1),
using bootstrap samples of the literature-derived occult tumor
(size, stage) values, and durations of the occult interval sampled
Figure 3. Early detection sensitivity as a function of tumor size detection threshold. The predicted sensitivity of a hypothetical early
detection test is shown as a function of the tumor size detection threshold and frequency of a hypothetical screening test (see Methods). Results are
shown for two populations of women: (A) Normal-risk women receiving normal care and monitoring; (B) High-risk women subjected to careful
monitoring (e.g. BRCA1 mutation carriers).
doi:10.1371/journal.pmed.1000114.g003
Figure 4. Reduction in 5-y mortality as a function of tumor size detection threshold. The predicted reduction in 5-y mortality from serous
ovarian cancer is shown as a function of the tumor size detection threshold and frequency of a hypothetical screening test (see Methods). Results are
shown for two populations of women: (A) Normal-risk women receiving normal care and monitoring; (B) High-risk women subjected to careful
monitoring (e.g., BRCA1 mutation carriers).
doi:10.1371/journal.pmed.1000114.g004
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analyses, the 95% CI for the detection threshold required to
achieve 80% sensitivity in early detection with an annual screen
was 0.1–1.7 cm; for 50% sensitivity, the 95% CI for the required
detection threshold was 0.4–3.2 cm (in normal-risk women). The
95% CI for the detection threshold required to achieve a 50%
reduction in 5-y mortality with an annual screen was 0.1–2.3 cm
for normal-risk women and 0.1–2.1 cm for high-risk women (see
Figure S5).
Perhaps the most likely systematic error in the data on which we
based our model was understaging of the occult tumors discovered
by PBSO. Although we assumed in our model that the stages of all
the occult tumors were correctly reported (i.e., 0% understaging),
it is likely that a significant fraction of these cancers were
understaged, as an overwhelming majority (.90%) were only
discovered postoperatively by microscopic examination, indicating
that surgical staging was incomplete. Our sensitivity analysis shows
that, if understaging of the occult tumors was a significant
problem, our conclusions regarding the performance requirements
for early detection are likely to be overly optimistic (Table 3;
Figures S7C and S8C).
A second potential source of systematic bias is our estimate of
the distribution of tumor diameters at diagnosis, since these results
were based on limited available data (see Methods, data sources).
We found that increasing or decreasing our estimates of tumor
sizes at clinical presentation in BRCA1 mutation carriers or in
normal-risk women over a 2-fold range had a negligible effect on
our conclusions (Table 3; Figures S7A, S7B, S8A, and S8B).
Third, we investigated the effects of errors in our estimate of
the duration of the occult period, which could potentially arise
because of systematic biases in the data on which we based
our estimates of incidence or prevalence (see Methods, data
sources). Doubling or halving the estimated duration of the
occult period would only slightly alter estimates of the
detection threshold required to achieve a given early detection
test sensitivity or mortality reduction (Table 3; Figures S7D
and S8D).
Lastly, we considered the possibility that a fraction of occult
cancers, if left untreated, would never progress to stage III or IV.
Our default assumption was that all of the occult cancers would
progress and grow to become clinically significant, yet there is
evidence that a significant fraction of occult cancers at other sites
(e.g., prostate, kidney, and breast [37]) never progress to a
clinically significant stage. If instead only 50% of tumors were
destined to be ‘‘progressive,’’ a screening test would need to detect
tumors at a slightly smaller size to achieve an equivalent early
detection sensitivity or mortality reduction (Table 3).
Discussion
Our challenge was to understand what serous ovarian cancers
look like before signs or symptoms lead to their clinical detection.
PBSOs, in women with no evidence of serous cancer, provide the
only immediately available window on these occult cancers. By
aggregating and analyzing the results of all available prospective
PBSO studies, we estimated the size and stage distribution of
occult serous ovarian cancers, the duration of the ‘‘window of
opportunity’’ for early detection, and the location of occult serous
cancers (see Figure 1).
With respect to tumor stage, the results were encouraging for
early detection; most occult cancers in BRCA1 carriers were still at
an early stage, either CIS, stage I, or stage II. It is important to
note, however, that an overwhelming majority (.90%) of these
cancers were only discovered postoperatively by microscopic
examination, indicating that surgical staging was incomplete; it is
therefore likely that some of these cancers were understaged.
Indeed, several studies have reported development of primary
peritoneal serous cancers within a few years of a PBSO in which
no malignancy was found, suggesting that some cancers are missed
or understaged in these studies [7,8,10,13,14,22].
Our analysis of the duration of time that tumors spend at each
stage while still occult was also encouraging with regard to the
feasibility of early detection. By comparing the prevalence of
occult tumors at each stage to the incidence of serous ovarian
cancer in a matched population of women (BRCA1 carriers, similar
age), we estimated that serous tumors spend approximately 4.3 y
as histopathologically detectable but clinically occult early stage
tumors. This 4.3-y window represents the period of time during
which we could presumably save lives through early detection.
We also estimated that, on average, serous ovarian cancers have
already progressed to a late stage nearly 1 y prior to their
discovery. This conclusion is consistent with the results of several
studies of BRCA1 carriers, which found that most serous cancers
present at an advanced stage [32,38,39], and with screening
studies, which also find that most of these cancers are already
advanced when discovered, whether by conventional screening or
by symptomatic presentation [23,40–49]. Presumably, the median
interval between progression to advanced stage and clinical
diagnosis, and the overall duration of the occult period, would
be correspondingly longer in women who are monitored less
Table 3. Sensitivity analyses: effects of systematic errors in model inputs.
Results with
Default Values
a
Percent
Understaging
Size at Clinical
dx (BRCA1)
Size at Clinical dx
(Normal-Risk)
Duration of
Occult Period
Percent Progressive
Tumors
Input value
b — 20% 50% 0.56 26 4 cm 16 cm 2.5 y 10.2 y 50%
50% ED sensitivity
(cm)
c
1.1 0.7 0.3 1.2 1.2 0.7 1.7 0.9 1.5 0.9
50% mortality
reduction (cm)
d
0.5 0.2 ,0.1 0.5 0.5 0.3 0.6 0.3 0.6 0.3
aDefault values were as follows: percent understaging, 0%; size at clinical diagnosis (dx) (BRCA1) (see Table S3, reference [35]); size at clinical diagnosis (normal risk), 8 cm
diameter; duration of occult period, 5.1 y (see Results); percent progressive tumors, 100%.
bValues shown in first row were used as inputs into the model shown in Figure 1. All other variables were fixed at default values (see footnote a).
cValues indicate the size of tumor (diameter) that an early detection test must detect in order to achieve 50% early detection sensitivity given the modified model input
specified in the relevant column header.
dValues shown indicate the size of tumor (diameter) that an early detection test must detect in order to achieve a 50% reduction in 5-y mortality given the modified
model input specified in the relevant column header.
doi:10.1371/journal.pmed.1000114.t003
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analysis.
With respect to tumor size, our results were sobering: we
estimated that occult, early-stage (CIS, stage I, or stage II) serous
ovarian cancers (in BRCA1 women) have a median diameter of less
than 0.3 cm and spend, on average, more than 90% of the duration
of the windowof opportunity for earlydetection at a diameter of less
than 0.9 cm (Figure S9). Indeed, many occult cancers had already
progressed to stage III or IV when discovered at PBSO, and the
majority of these advanced cancers were 1 cm in diameter or
smaller. Remarkably, more than 90% of the occult cancers were
missed both during surgery and on gross examination and
discovered only upon microscopic examination (Table S1).
It is also worth noting that our analysis adds to a growing body
of evidence that ‘‘ovarian’’ cancers occur frequently in the
Fallopian tubes—we found that occult serous ‘‘ovarian’’ cancers
in BRCA1 mutation carriers are approximately twice as likely to be
found in the Fallopian tubes as in the ovaries [14,15,18,20,22].
We further used the PBSO data, together with data on tumor
sizes at clinical diagnosis, to build statistical models for the growth,
progression, and diagnosis of serous ovarian cancers. The results of
our growth rate estimation highlighted the explosive growth of
advanced stage serous ovarian cancers. We estimated that late stage
occult ovarian tumors double in volume every 2.5 mo, a conclusion
that is reinforced by a previous study that found that most advanced
high-grade serous tumors were undetectable by transvaginal
ultrasonography several (2–12) mo prior to diagnosis, despite their
relatively large size (mean 5.8 cm) at diagnosis [50]. It’s interesting
to note that if we assume that early-stage serous ovarian cancers
grow exponentially at a constant rate beginning with the first
cancerous progenitor cell, and that the cancer cells are roughly
15 mm in diameter, extrapolation from this growth model suggests
that on average these cancers ‘‘originate’’ about 8 y prior to
progression to stage III, and 9 y prior to clinical diagnosis.
We estimated the performance of hypothetical screening tests as
a function of their tumor-size threshold for detection and of
screening frequency using our models for tumor growth,
progression, and diagnosis. Our most important conclusion with
respect to early detection was that an annual screening test of
normal-risk women would need to detect tumors less than 1.3 cm
in diameter in order to achieve 50% sensitivity, or less than 0.4 cm
in diameter to reach 80% sensitivity in detecting these cancers
before they progress to stage III+ (Figure 3).
Combining the modeling results with stage-specific survival
statistics suggests that to achieve a 50% reduction in 5-y mortality
from serous ovarian cancer in a normal-risk population, an annual
screen would need to detect tumors 0.5 cm in diameter or smaller
(Figure 4). Our estimates of potential survival benefits of early
detection assumed that the stage-specific survival rates for screen-
detected tumors would be the same as those for tumors diagnosed
on the basis of signs and symptoms; however, it is quite possible
that detecting even advanced tumors at a smaller size might yield
additional survival gains. Our analysis of potential mortality
reductions from screening ignored the effects of lead-time bias on
stage-specific 5-y survival rates, and did not take into account the
potential hazards of overdiagnosis. Had we considered either of
these factors our estimates of the survival gains for a given early-
detection test performance would almost certainly have been
lower.
Sensitivity analyses (Table 3; Figures S7, S8) suggest that our
major conclusions regarding the performance requirements for a
successful early detection strategy are remarkably robust; even
improbably large systematic biases or sampling errors in the
critical data-driven parameters of the model, (size distribution of
tumors at diagnosis, extent of understaging, duration of the occult
period), lead to only slight changes in the results, which do not
alter the important conclusions.
We based our analyses on women carrying a mutation in
BRCA1, as they comprise the largest reasonably homogenous
defined subset of women who undergo PBSO. The extent to which
our findings apply to other ovarian cancers is uncertain. Clearly, it
would be a mistake to assume that they apply to ovarian cancers of
histological types other than serous; these are distinctly different
diseases, clinically and molecularly [3,4]. Whether our findings in
BRCA1 carriers can be generalized to serous ovarian cancers in
general, including sporadic or non-BRCA1 familial cases, is still an
important question. We were able to assess the latter directly,
using data from BRCA2 and other unspecified familial cancers,
and found no significant difference in our estimates of prevalence,
incidence, duration, size distributions, or locations of occult
cancers between these high-risk populations (Table S4). Further-
more, on the basis of current literature, the cancers in women with
BRCA1 mutations appear to be a reasonable model for sporadic
serous ovarian cancers. Several studies have compared hereditary
and sporadic ovarian cancers and found few significant differences
in either clinical or molecular characteristics. The most consis-
tently reported difference is in the distribution of tumor histologies;
BRCA1 mutation carriers tend almost exclusively to develop serous
ovarian cancer, whereas a considerable fraction of sporadic
ovarian cancers are of endometrioid, mucinous, or clear-cell
histology [38,39,51,52]. A few studies have reported small
differences in survival and in grade between sporadic and
hereditary serous ovarian cancers [38,53]. Unfortunately, most
studies comparing sporadic to hereditary cancers failed to stratify
results by histological type, making it difficult to compare serous
cases in BRCA1 mutation carriers to their sporadic counterparts.
Although we cannot take for granted that serous ovarian cancers
in general can be represented by the natural history model
described here, we are not aware of any data regarding sporadic
serous cancers that is inconsistent with this model. Moreover,
irrespective of their value as models for sporadic serous cancers,
understanding the early natural history of serous cancers in BRCA1
women is important. These women account for up to 10% of all
serous ovarian cancers and, as a readily identified high-risk
population, are likely to be the first group in which any potential
early detection strategy will be evaluated.
For many cancers, early detection is widely believed to be the
most promising strategy to save lives [6]. The parameters that we
estimated here based on a review of PBSO studies, and the
resulting model for the natural history of ovarian cancer, have
important implications for rational design of an early detection
strategy. The relatively long window of opportunity for detection
prior to progression to stage III or IV suggests that an annual
screen could be a viable screening strategy. Indeed, a universal
annual screen capable of detecting serous cancers 0.5 cm in
diameter might reduce 5-y mortality from this disease by 50%
(Figure 4). However, our analysis suggests that in order for an
annual screen of normal-risk women to achieve a moderate 50%
sensitivity in early detection of cancers that would otherwise be
diagnosed at an advanced stage, the assay would need to reliably
detect tumors of 1.3 cm in diameter (Figure 3).
The need to detect very small tumors has important
consequences for both the type of biomolecule and the type of
assay technology that are likely to be effective in an early detection
strategy. For a blood-based biomarker to be useful for early
detection, there must be a significant difference between the
maximum biomarker levels observed in the blood of almost all
cancer-free women and the levels characteristically observed in
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biomarker levels in the blood as a consequence of a 0.5-cm tumor
is likely to be extremely small, implying that the baseline levels
must be consistently lower still in an overwhelming majority of
ovarian cancer-free women in order for the difference to be
detectable and robust. A recently published mathematical model
relating secreted blood biomarker levels to tumor sizes illustrates
that tumors in the millimeter diameter range can only be detected
under ideal conditions of extremely high rates of biomarker
secretion by tumor-associated cells and essentially zero back-
ground from healthy cells; under more realistic conditions, using
known parameters of CA125 and PSA, detection limits are in the
several to many centimeter diameter range [54]. An addition
implication of the need to detect tiny tumors is that biomarker
discovery and validation will both require extremely sensitive
biomarker assays. This requirement is especially challenging in the
discovery phase, particularly for proteomic markers, as mass
spectrometry-based proteomics approaches are only recently
dipping into the nanogram/milliliter range for detection and
quantification—well above the range of serum concentrations
expected for proteins produced exclusively by subcentimeter-sized
tumors.
Most published studies have evaluated ovarian cancer biomark-
ers on the basis of their ability to detect ovarian cancer in women
with clinically apparent tumors [55–57]. An important implication
of our analysis is that these clinically apparent tumors are not good
models for the tumors that an effective early detection test would
need to detect. Indeed, our analyses show that early-stage serous
ovarian cancers are rarely more than a few millimeters in diameter.
In contrast, the infrequent serous cancers that present clinically
while still stage I or II are typically 8 cm or more in diameter (P.
Shaw and B. Rosen, unpublished data). Thus, by the time they
become clinically apparent, most serous ovarian cancers are more
than 200 times larger than the presymptomatic tumors a successful
early detection strategy must detect. We must therefore be
extremely cautious in extrapolating from the performance of serum
biomarkers in detecting clinically apparent tumors to utility in early
detection. Unfortunately, the magnitude of this leap is often
ignored; many reports of candidate blood biomarkers for ovarian
cancer assume that the detection of symptomatic stage I and II
tumors will translate to an effective early detection test. Some have
even used this fallacious reasoning to promote useless commercial
tests [56,58]. None of the biomarkers or biomarker panels reported
to date has come close to demonstrating the performance that,
according to our analysis, would be required for useful early
detection. Indeed, the few large prospective trials of screening for
ovarian cancer have yielded disappointing results [35,45,59,60]
It is likely that some combination of new biomarkers and new
approaches will be needed to meet the challenge of early detection.
Novel biomarkers that are truly unique to cancers (e.g., RNA or
protein products of oncogenic gene fusions)—if they exist—are
one attractive possibility. Detection of tumor biomarkers in
alternative biospecimens like proximal fluids (e.g., for ovarian
cancer, vaginal, or uterine lavage), rather than in blood, may be a
useful strategy for boosting signal to noise by both reducing
background from nonmalignant tissues and avoiding the problem
of biomarker dilution inherent in blood-based assays. Positron
emission tomography (PET) or ultrasound imaging of specific
molecular targets is another potentially promising approach to
early detection of ovarian cancers currently under investigation
[61,62]. Identification of adequately specific molecular markers
and development of assays or imaging probes that provide the
necessary sensitivity and signal to background ratio is still a great
challenge.
Given the critical importance of the parameters that we
estimated here for rational design of an early detection strategy,
we believe that it would be extremely valuable to perform similar
investigations into the early natural history of ovarian cancer in
normal-risk women, and of other cancers. In theory, it should be
possible to characterize occult ‘‘ovarian’’ cancers in the normal-
risk population by incorporating meticulous microscopic exami-
nation of the ovaries and Fallopian tubes into the pathological
examination of the resected tissues from routine hysterectomies, as
over 600,000 such operations are performed annually in the
United States alone (approximately half of which include salpingo-
oophorectomy [63]). For other cancers that develop in organs that
are rarely or never removed from healthy individuals, large-scale
autopsy studies including meticulous microscopic examination of
target organs could potentially provide the necessary data. Such a
strategy would be extremely challenging, due not only to the
significant cost, but also to the relative rarity of autopsies today,
the lack of detailed microscopic examination of apparently normal
tissues, and the lack of a coordinated framework for systematically
collecting data from autopsies. Nevertheless, we believe that
understanding the early natural history of cancer is of such critical
importance that the cost and effort would be justified.
Supporting Information
Figure S1 Size distribution models for serous ovarian cancers at
clinical diagnosis. The distributions of sizes (diameters) of tumors
at clinical diagnosis are shown for both a high-risk population (i.e.,
BRCA1 women); and a normal-risk population. For the high-risk
population, tumor diameters were modeled on the basis of sizes
reported in a large study of screening for ovarian cancer [35]. The
diameters reported in that study were smoothed with a log-normal
kernel; for tumors diagnosed in the intervals between screens
(whose sizes were not reported in the screening study), the sizes at
diagnosis were assumed to be log-normally distributed around a
mean of 8 cm. For the normal-risk population, tumor diameters
were assumed to be log-normally distributed with a mean of 8 cm.
Found at: doi:10.1371/journal.pmed.1000114.s001 (0.66 MB
EPS)
Figure S2 Probability distributions for true incidence, preva-
lence, and occult period duration of serous ovarian cancer in
BRCA1 women given the observed data (see Methods). (A)
Prevalence; (B) Incidence; (C) Duration of occult period; (D)
Duration of early-stage occult period.
Found at: doi:10.1371/journal.pmed.1000114.s002 (0.97 MB
EPS)
Figure S3 Model tumor progression as a function of tumor size.
Results of a Kaplan-Meier analysis of 1,000 bootstrap samples of
the tumor (size, stage) data for occult serous cancers discovered by
PBSO, to estimate the risk of tumor progression (see Methods).
Results are shown for progression to stage II+ and for progression
to stage III+, with and without normal kernel smoothing of the
input tumor size data. (A) Progression to stage II+; with
smoothing; (B) Progression to stage II+; no smoothing; (C)
Progression to stage III+; with smoothing; (D) Progression to
stage III+; no smoothing.
Found at: doi:10.1371/journal.pmed.1000114.s003 (1.57 MB
EPS)
Figure S4 Observed versus model-predicted sizes of occult
serous ovarian cancers. (A) Early-stage (CIS, stage I and II) occult
tumors and (B) advanced-stage (stage III and IV) occult tumors.
Observed sizes were obtained directly from PBSO studies (Table
S1). Predicted sizes were obtained from the Monte Carlo
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growth parameters and size-dependent progression models derived
using 200 bootstrap samples of the occult tumor (size, stage) data.
Found at: doi:10.1371/journal.pmed.1000114.s004 (3.81 MB
TIF)
Figure S5 CIs for early detection test performance versus tumor
detection threshold. Bootstrap CIs are shown for our estimates of
early detection test performance requirements as indicated by the
legend (see Methods). All results shown here are for an annual
screening test. (A) and (B) Early detection test sensitivity versus
detection threshold. (A) Normal-risk women; (B) High-risk women
(i.e., BRCA1 women); (C) and (D) Reduction in 5-y mortality
versus detection threshold. (C) Normal-risk women; (D) High-risk
women (i.e., BRCA1 women).
Found at: doi:10.1371/journal.pmed.1000114.s005 (1.07 MB
EPS)
Figure S6 Model tumor characteristics. (A, B) Bootstrap
probability distributions for tumor growth rates in BRCA1 women
(see Methods): (A) Stage CIS, I, II tumors; (B) Stage III, IV tumors.
(C, D) Monte-Carlo models for tumor life histories (see Methods).
Fifty model tumor trajectories are shown in each of two
populations: (C) High-risk women; (D) Normal-risk women.
Found at: doi:10.1371/journal.pmed.1000114.s006 (1.51 MB
EPS)
Figure S7 Effects of systematic errors in source data on estimates
of test sensitivity versus detection threshold. For each of four
model input variables, we varied the input over several fold and
plotted the resulting estimates of early-detection sensitivity as a
function of tumor size detection threshold (see Methods). (A–C)
Results assuming annual screening tests. (D) Tumor size detection
thresholds needed for 50% sensitivity. (A) Effect of tumor size at
clinical diagnosis in normal-risk patients. Our primary analyses
assumed a mean tumor diameter at diagnosis of 8 cm. Results are
shown for this size as well as the other tumor sizes indicated in the
legend. (B) Effect of tumor size at clinical diagnosis in high-risk
patients. Our primary analyses assumed that serous ovarian
cancers in normal-risk women present at sizes corresponding to
the distribution reported in [35]. Results are shown for this size
(16) as well as for the other size distributions indicated in the
legend (e.g., 26=all sizes multiplied by 2 relative to the 16size
distribution). (C) Effect of understaging of tumors found by PBSO.
Our primary analyses assumed 0% understaging. Results are
shown for no understaging (0%) through 100%, where the
indicated percentage of the occult tumors used for our analysis
were adjusted to be one FIGO stage more advanced than
reported. (D) Effect of variation in duration of occult period. The
duration estimate used in our primary analyses is indicated by 16.
‘‘Fold error in duration estimate’’ is the ratio of the estimated
duration to the true duration of the occult period.
Found at: doi:10.1371/journal.pmed.1000114.s007 (1.32 MB
EPS)
Figure S8 Effects of systematic errors in source data on estimates
of mortality reduction versus detection threshold. For each of four
model input variables, we varied the input over several fold and
plotted the resulting estimates of reduction in 5-y mortality as a
function of tumor size detection threshold (see Methods). (A–C)
Results assuming annual screening tests. (D) Tumor size detection
thresholds needed for 50% reduction in 5-y mortality. (A) Effect of
tumor size at clinical diagnosis in normal-risk patients. Our
primary analyses assumed a mean tumor diameter at diagnosis of
8 cm. Results are shown for this size as well as the other tumor
sizes indicated in the legend. (B) Effect of tumor size at clinical
diagnosis in high-risk patients. Our primary analyses assumed that
serous ovarian cancers in normal-risk women present at sizes
corresponding to the distribution reported in [35]. Results are
shown for this size (16) as well as for the other sizes indicated by
the fold changes in the legend (e.g., 26=all sizes multiplied by 26
relative to the 16size distribution). (C) Effect of understaging of
tumors found by PBSO. Our primary analyses assumed 0%
understaging. Results are shown for no understaging (0%) through
100%, where the indicated percentage of the occult tumors used
for our analysis were adjusted to be one FIGO stage more
advanced than reported. (D) Effect of variation in duration of
occult period on threshold for 50% mortality reduction. The
duration estimate used in our primary analyses is indicated by 16.
‘‘Fold error in duration estimate’’ is the ratio of the estimated
duration to the true duration of the occult period.
Found at: doi:10.1371/journal.pmed.1000114.s008 (1.31 MB
EPS)
Figure S9 Cumulative distribution of sizes of occult early-stage
tumors discovered by PBSO. If we assume that these early-stage
occult tumors were discovered by PBSO at times uniformly
sampled from the window of opportunity for early detection, the
cumulative percentage of tumors below a specified size represents
the fraction of the window of opportunity during which tumors are
less than that size. Thus, this analysis implies that tumors are less
than 3 mm in diameter for more than 50% of the window of
opportunity for early detection, and less than 9 mm in diameter
for more than 90% of this window of opportunity.
Found at: doi:10.1371/journal.pmed.1000114.s009 (0.63 MB
EPS)
Table S1 Detailed findings in PBSO studies on which analyses
of occult serous cancers were based.
Found at: doi:10.1371/journal.pmed.1000114.s010 (0.05 MB
XLS)
Table S2 Summary of studies used to estimate incidence of
serous ovarian cancer in BRCA1 women.
Found at: doi:10.1371/journal.pmed.1000114.s011 (0.04 MB
XLS)
Table S3 Summary of tumors used for modeling distribution of
sizes at diagnosis in a closely monitored population.
Found at: doi:10.1371/journal.pmed.1000114.s012 (0.02 MB
XLS)
Table S4 Comparison of occult tumor characteristics in BRCA1
women versus all high-risk women.
Found at: doi:10.1371/journal.pmed.1000114.s013 (0.02 MB
XLS)
Text S1 R program for calculating probability distributions and
CIs for prevalence, incidence, and duration of occult period and
stages.
Found at: doi:10.1371/journal.pmed.1000114.s014 (0.02 MB
DOC)
Text S2 R program for modeling the preclinical natural history
of serous cancer-stage progression as a function of size, growth
rates, sensitivity of early-detection screening programs and
expected reduction in 5-y mortality as a function of size threshold
for tumor detection and screening interval.
Found at: doi:10.1371/journal.pmed.1000114.s015 (0.02 MB
DOC)
Text S3 R program for calculating probability distributions and
CIs for prevalence, incidence, and duration of occult period and
stages, assuming that 50% of the early tumors discovered by PBSO
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contribute to incidence or mortality).
Found at: doi:10.1371/journal.pmed.1000114.s016 (0.08 MB
DOC)
Text S4 R program for modeling early-detection sensitivity and
changes in 5-y mortality as a function of size threshold for tumor
detection and screening interval, assuming that 50% of the early
tumors discovered by PBSO will never progress to a clinically
significant stage (i.e. they do not contribute to incidence or
mortality).
Found at: doi:10.1371/journal.pmed.1000114.s017 (0.01 MB
DOC)
Text S5 R program for calculating probability distributions and
CIs for prevalence, incidence, and duration of occult period and
stages. This is the same as Text S1, except it runs faster at the
expense of a small reduction in the precision of the estimates. Note
that the graphs used in Figure S1 were produced using Text S1.
Found at: doi:10.1371/journal.pmed.1000114.s018 (0.08 MB
DOC)
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Background. Every year about 190,000 women develop
ovarian cancer and more than 140,000 die from the disease.
Ovarian cancer occurs when a cell on the surface of the
ovaries (two small organs in the pelvis that produce eggs) or
in the Fallopian tubes (which connect the ovaries to the
womb) acquires genetic changes (mutations) that allow it to
grow uncontrollably and to spread around the body
(metastasize). For women whose cancer is diagnosed when
it is confined to the site of origin—ovary or Fallopian tube—
(stage I disease), the outlook is good; 70%–80% of these
women survive for at least 5 y. However, very few ovarian
cancers are diagnosed this early. Usually, by the time the
cancer causes symptoms (often only vague abdominal pain
and mild digestive disturbances), it has spread into the pelvis
(stage II disease), into the space around the gut, stomach,
and liver (stage III disease), or to distant organs (stage IV
disease). Patients with advanced-stage ovarian cancer are
treated with surgery and chemotherapy but, despite recent
treatment improvements, only 15% of women diagnosed
with stage IV disease survive for 5 y.
Why Was This Study Done? Most deaths from ovarian
cancer are caused by serous ovarian cancer, a tumor subtype
that is rarely diagnosed before it has spread. Early detection
of serous ovarian cancer would save the lives of many
women but no one knows what these cancers look like
before they spread or how long they grow before they
become clinically apparent. Learning about this occult
(hidden) period of ovarian cancer development by
observing tumors from their birth to late-stage disease is
not feasible. However, some aspects of the early natural
history of ovarian cancer can be studied by using data
collected from healthy women who have had their ovaries
and Fallopian tubes removed (prophylactic bilateral
salpingo-oophorectomy [PBSO]) because they have
inherited a mutated version of the BRCA1 gene that
increases their ovarian cancer risk. In a few of these
women, unsuspected ovarian cancer is discovered during
PBSO. In this study, the researchers identify and analyze the
available reports on occult serous ovarian cancer found this
way and then develop mathematical models describing the
early natural history of ovarian cancer.
What Did the Researchers Do and Find? The researchers
first estimated the time period during which the detection of
occult tumors might save lives using the data from these
reports. Serous ovarian cancers, they estimated, spend more
than 4 y as in situ (a very early stage of cancer development),
stage I, or stage II cancers and about 1 y as stage III and IV
cancers before they become clinically apparent. Next, the
researchers used the data to develop mathematical models
for the growth, progression, and diagnosis of serous ovarian
cancer (the accuracy of which depends on the assumptions
used to build the models and on the quality of the data fed
into them). These models indicated that, for most of the
occult period, serous cancers had a diameter of less than
1 cm (too small to be detected during surgery or by gross
examination of the ovaries or Fallopian tubes) and that more
than half of serous cancers had advanced to stage III/IV by
the time they measured 3 cm across. Furthermore, to enable
the detection of half of serous ovarian cancers before they
reached stage III, an annual screening test would need to
detect cancers with a diameter of 1.3 cm and to halve deaths
from serous ovarian cancer, an annual screening test would
need to detect 0.5-cm diameter tumors.
What Do These Findings Mean? These findings suggest
that the time period over which the early detection of serous
ovarian cancer would save lives is surprisingly long. More
soberingly, the authors find that a test that is sensitive and
specific enough to take advantage of this ‘‘window of
opportunity’’ would need to detect tumors hundreds of
times smaller than clinically apparent serous cancers. So far
no ovarian cancer-specific protein or other biomarker has
been identified that could be used to develop a test that
comes anywhere near this level of performance.
Identification of truly ovarian cancer-specific biomarkers or
novel strategies will be needed in order to take advantage of
the window of opportunity. The stages prior to clinical
presentation of other lethal cancers are still very poorly
understood. Similar studies of the early natural history of
these cancers could help guide the development of rational
early detection strategies.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000114.
N The US National Cancer Institute provides a brief
description of what cancer is and how it develops and
information on all aspects of ovarian cancer for patients
and professionals. It also provides a fact sheet on BRCA1
mutations and cancer risk (in English and Spanish)
N The UK charity Cancerbackup also provides information
about all aspects of ovarian cancer
N MedlinePlus provides a list of links to additional informa-
tion about ovarian cancer (in English and Spanish)
N The Canary Foundation is a nonprofit organization
dedicated to development of effective strategies for early
detection of cancers including ovarian cancer.
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